The β3-adrenergic receptor agonist mirabegron improves glucose homeostasis in obese humans - Finlin, Brian S.; Memetimin, Hasiyet; Zhu, Beibei; Confides, Amy L.; Vekaria, Hemendra J.; El Khouli, Riham H.; Johnson, Zachary R.; Westgate, Philip M.; Chen, Jianzhong; Morris, Andrew J.; Sullivan, Patrick G.; Dupont-Versteegden, Esther E.; et al. (The Journal of clinical investigation, 2020)
Keywords: Acetanilides - administration & dosage; Adipocytes; Adipocytes - metabolism; Adipocytes - pathology; Adipose tissue (brown); Adipose Tissue, Beige - metabolism; Adipose Tissue, Beige - pathology; Adrenergic beta-3 Receptor Agonists - administration & dosage; Adrenergic receptors; Adult; Aged; Agonists; Biomedical research; Biopsy; Blood Glucose - metabolism; Clinical Medicine; Cold; Diabetes; Female; Gene expression; Gene Expression Regulation - drug effects; Glucose; Glucose tolerance; Hemoglobin; Homeostasis; Humans; Insulin; Insulin resistance; Lipids; Lipolysis; Macrophages; Male; Metabolism; Middle Aged; Muscle, Skeletal - metabolism; Muscle, Skeletal - pathology; Musculoskeletal system; Nervous system; Obesity; Obesity - blood; Obesity - drug therapy; Obesity - pathology; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha - biosynthesis; Skeletal muscle; Thermogenesis; Thiazoles - administration & dosage; Triglycerides; Weight control; Glucose metabolism; Obesity; Adipose tissue; Metabolism; Clinical Trials